Targeting IL-17 with ixekizumab in patients with psoriasis

Immunotherapy

Volumn 7, Issue 9, 2015, Pages 957-966

  Dyring Andersen, Beatrice ^a   Skov, Lone ^a   Zachariae, Claus ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

IL 17A; IL 17F; IL 22; ixekizumab; psoriasis

Indexed keywords

IMMUNOGLOBULIN G4; INTERLEUKIN 17; INTERLEUKIN 17F; IXEKIZUMAB; MONOCLONAL ANTIBODY;

ARTICLE; CELL MATURATION; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CYTOKINE RELEASE; DIFFERENTIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELIMINATION HALF-LIFE; HEADACHE; HUMAN; IMMUNOGENICITY; LYMPHOID CELL; MAST CELL; NEUTROPENIA; NEUTROPHIL; NONHUMAN; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN TARGETING; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION; ANIMAL; DENDRITIC CELL; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; KERATINOCYTE; METABOLISM; MOLECULARLY TARGETED THERAPY;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS AS TOPIC; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-17; KERATINOCYTES; MOLECULAR TARGETED THERAPY; PSORIASIS;

EID: 84947554133     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.15.63     Document Type: Article

References (53)

1. Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J. Invest. Dermatol. 133(2), 377-385 (2013).
2. Mosmann TR, Coffman RL. Th1 and Th2 cells: different patterns of lymphokine functional properties. Annu. Rev. Immunol. 7, 145-173 (1989).
3. Rouvier E, Luciani MF, Mattéi MG, Denizot F, Golstein P. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J. Immunol. 150(12), 5445-5456 (1993).
4. Gaffen SL. Recent advances in the IL-17 cytokine family. Curr. Opin. Immunol. 23(5), 613-619 (2011).
5. Yao Z, Painter SL, Fanslow WC et al. Human IL-17: A novel cytokine derived from T cells. J. Immunol. 155, 5483-5486 (1995).
6. Fossiez F, Djossou O, Chomarat P et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J. Exp. Med. 183(6), 2593-2603 (1996).
7. Res PCM, Piskin G, de Boer OJ et al. Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS ONE 5(11), e14108 (2010).
8. Cai Y, Shen X, Ding C et al. Pivotal role of dermal IL-17-producing γδ T cells in skin inflammation. Immunity 35(4), 596-610 (2011).
9. Kim BS. Innate lymphoid cells in the skin. J. Invest. Dermatol. 135(3), 673-678 (2014).
10. Toy D, Kugler D, Wolfson M et al. Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J. Immunol. 177(1), 36-39 (2006).
11. Yao Z, Spriggs MK, Derry JM et al. Molecular characterization of the human interleukin (IL)-17 receptor. Cytokine 9(11), 794-800 (1997).
12. Ely LK, Fischer S, Garcia KC. Structural basis of receptor sharing by interleukin 17 cytokines. Nat. Immunol. 10(12), 1245-1251 (2009).
13. Ge D, You Z. Expression of interleukin-17RC protein in normal human tissues. Int. Arch. Med. 1(1), 19 (2008).
14. Shen F, Gaffen SL. Structure-function relationships in the IL-17 receptor: implications for signal transduction and therapy. Cytokine 41(2), 92-104 (2008).
15. Van Beelen AJ, Teunissen MBM, Kapsenberg ML, de Jong EC. Interleukin-17 in inflammatory skin disorders. Curr. Opin. Allergy Clin. Immunol. 7(5), 374-81 (2007).
16. Teunissen MBM, Koomen CW, de Waal Malefyt R, Wierenga EA, Bos JD. Interleukin-17 and interferon-γ synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J. Invest. Dermatol. 111(4), 645-649 (1998).
17. Peric M, Koglin S, Kim S-M et al. IL-17A enhances vitamin D3-induced expression of cathelicidin antimicrobial peptide in human keratinocytes. J. Immunol. 181(12), 8504-8512 (2008).
18. Nograles KE, Zaba LC, Guttman-Yassky E et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br. J. Dermatol. 159(5), 1092-1102 (2008).
19. Cho K-A, Suh JW, Lee KH, Kang JL, Woo S-Y. IL-17 and IL-22 enhance skin inflammation by stimulating the secretion of IL-1β by keratinocytes via the ROS-NLRP3-caspase-1 pathway. Int. Immunol. 24(3), 147-158 (2012).
20. Kim T-G, Jee H, Fuentes-Duculan J et al. Dermal clusters of mature dendritic cells and T cells are associated with the CCL20/CCR6 chemokine system in chronic psoriasis. J. Invest. Dermatol. 134(5), 1462-1465 (2014).
21. El-Moaty Zaher HA, El-Komy MHM, Hegazy RA, Mohamed El Khashab HA, Ahmed HH. Assessment of interleukin-17 and vitamin D serum levels in psoriatic patients. J. Am. Acad. Dermatol. 69(5), 840-842 (2013).
22. Johnston A, Fritz Y, Dawes SM et al. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J. Immunol. 190(5), 2252-2262 (2013).
23. Lee E, Trepicchio WL, Oestreicher JL et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 199(1), 125-130 (2004).
24. Toichi E, Torres G, McCormick TS et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J. Immunol. 177(7), 4917-4926 (2006).
25. Griffiths CEM, Strober BE, van de Kerkhof P et al. Comparison of ustekinumab and etanercept for moderate-tosevere psoriasis. N. Engl. J. Med. 362(2), 118-128 (2010).
26. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu. Rev. Immunol. 27, 485-517 (2009).
27. Tham L-S, Tang C-C, Choi S-L, Satterwhite JH, Cameron GS, Banerjee S. Population exposure-response model to support dosing evaluation of ixekizumab in patients with chronic plaque psoriasis. J. Clin. Pharmacol. 54(10), 1117-1124 (2014).
28. Genovese MC, Greenwald M, Cho C-S et al. A Phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis Rheumatol. 66(7), 1693-1704 (2014).
29. Krueger JG, Fretzin S, Suárez-Fariñas M et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J. Allergy Clin. Immunol. 130(1), 145-154; e9 (2012).
30. Leonardi C, Matheson R, Zachariae C et al. Antiinterleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med. 366(13), 1190-1199 (2012).
31. Gordon KB, Leonardi CL, Lebwohl M et al. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J. Am. Acad. Dermatol. 71(6), 1176-1182 (2014).
32. Genovese MC, Van den Bosch F, Roberson SA et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A Phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheumatol. 62(4), 929-939 (2010).
33. Hsu L, Snodgrass BT, Armstrong AW. Antidrug antibodies in psoriasis: A systematic review. Br. J. Dermatol. 170, 261-273 (2014).
34. Fernandez-Flores a. The role of IgG4 in cutaneous pathology. Rom. J. Morphol. Embryol. 53(2), 221-231 (2012).
35. Reich K, Armstrong A, Blauvelt A et al. Secukinumab, a novel anti-IL-17A antibody, exhibits low immunogenicity in clinical trials and human in vitro Assays. Presented at: 73 Annual Meeting, American Association. CA, USA, 20-24 March (2015).
36. KolbingerF, Bruin G, Valentin MA et al. Secukinumab rapidly reduces markers of both keratinocyte proliferation and skin integrity in psoriasis. Presented at: 73 Annual Meeting, American Association. CA, USA, 20-24 March (2015).
37. Zaba LC, Suárez-Fariñas M, Fuentes-Duculan J et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J. Allergy Clin. Immunol. 124(5), 1022-1030.e395 (2009).
38. Langley RG, Rich P, Menter A et al. Improvement of scalp and nail lesions with ixekizumab in a Phase 2 trial in patients with chronic plaque psoriasis. J. Eur. Acad. Dermatol. Venereol. doi:10.1111/jdv.12996 (2015) (Epub ahead of print).
39. Saeki H, Nakagawa H, Ishii T et al. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J. Eur. Acad. Dermatol. Venereol. 29(6), 1148-1155 (2015).
40. Chen Y, Qian T, Zhang D, Yan H, Hao F. Clinical efficacy and safety of anti-IL-17 agents for the treatment of patients with psoriasis. Immunotherapy 9, 1-15 (2015).
41. Papp KA, Leonardi C, Menter A et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 366(13), 1181-1189 (2012).
42. Papp KA, Langley RG, Sigurgeirsson B et al. Efficacy and safety of secukinumab in the treatment of moderateto-severe plaque psoriasis: A randomized, double-blind, placebo-controlled Phase II dose-ranging study. Br. J. Dermatol. 168(2), 412-421 (2013).
43. Aujla SJ, Chan YR, Zheng M et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat. Med. 14(3), 275-281 (2008).
44. Ye P, Rodriguez FH, Kanaly S et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J. Exp. Med. 194(4), 519-528 (2001).
45. Ishigame H, Kakuta S, Nagai T et al. Differential roles of interleukin-17A and-17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity 30(1), 108-119 (2009).
46. Puel A, Cypowyj S, Bustamante J et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 332(6025), 65-68 (2011).
47. Boisson B, Wang C, Pedergnana V et al. An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis. Immunity 39(4), 676-686 (2013).
48. Papp K, Leonardi C, Menter A et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J. Am. Acad. Dermatol. 71(6), 1183-1190.e3 (2014).
49. Williams B. Pain in the mouth: mucocutaneous findings associated with IL-17 inhibition. Presented at: 73 Annual Meeting, American Association. CA, USA, 20-24 March (2015).
50. Griffiths CEM, Papp K, Rivas E, Nakagawa H, Gong Y, Fox T PC. Secukinumab shows efficacy in subjects regardless of previous exposure to biologic therapy: A pooled subanalysis from four Phase 3 clinical trials in psoriasis. Presented at: 73 Annual Meeting, American Association. CA, USA, 20-24 March (2015).
51. Puig L. PASI90 response: The new standard in therapeutic efficacy for psoriasis. J. Eur. Acad. Dermatol. Venereol. 29(4), 645-648 (2015).
52. Bauer E, Lucier J, Furst DE. Brodalumab-an IL-17RA monoclonal antibody for psoriasis and psoriatic arthritis. Expert Opin. Biol. Ther. 15(6), 883-893 (2015).
53. Hueber W, Sands BE, Lewitzky S et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61(12), 1693-1700 (2012).